The European Commission has announced that Takeda Pharamceutical’s diabetes medication, Actos, can still be prescribed in the country after safety reviews were done.
Although the medication will still be able to be prescribed, the warning label on it will be updated with information that the use of the product for long periods of time may increase the patient’s risk of developing bladder cancer.
The main ingredient in Actos, pioglitazone, has been linked to this increased risk and the European Medicines Agency requested that all products with this ingredient remain options for diabetes treatment even though the safety concerns were voiced.
In July 2011, a review was ordered in the medication, as well as more extensive warning labels. In October of last year, the EMA stated that it only be prescribed if other treatments did not work for the patient. France and Germany suspended the use of pioglitazone drugs while an extensive review was done. Takeda has continued to state that Actos is an important treatment option for type 2 diabetes.
If you or a loved one has used Actos and developed bladder cancer as a result, you need experienced representation that may be able to help you receive the compensation you deserve. Contact the Actos bladder cancer lawsuit of Williams Kherkher by calling 800-641-9810.